Arformoterol

Arformoterol

Clinical data
Trade names	Brovana
Other names	Arformoterol tartrate (USAN US)
AHFS/Drugs.com	Monograph
MedlinePlus	a602023
License data	US DailyMed: Arformoterol
Routes of administration	Inhalation
ATC code	None
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Protein binding	52–65%
Elimination half-life	26 hours
Identifiers
IUPAC name N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl) propan-2-yl]amino]ethyl] phenyl]formamide
CAS Number	67346-49-0 Y
PubChem CID	3083544
IUPHAR/BPS	7479
DrugBank	DB01274 Y
ChemSpider	2340731 Y
UNII	F91H02EBWT
KEGG	D07463 D02981
ChEBI	CHEBI:408174 Y
ChEMBL	ChEMBL1201137 N
CompTox Dashboard (EPA)	DTXSID1023077 DTXSID40110071, DTXSID1023077
Chemical and physical data
Formula	C19H24N2O4
Molar mass	344.411 g·mol−1
InChI InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1 Y Key:BPZSYCZIITTYBL-YJYMSZOUSA-N Y
NY (what is this?)  (verify)

Arformoterol, sold under the brand name Brovana among others, is a medication used for the treatment of chronic obstructive pulmonary disease (COPD).

It is a long-acting β₂ adrenoreceptor agonist (LABA) and it is the active (R,R)-(−)-enantiomer of formoterol. It was approved for medical use in the United States in October 2006. It is available as a generic medicine.

Medical uses

Arformoterol is indicated for the maintenance treatment of bronchoconstriction in people with chronic obstructive pulmonary disease (COPD).

External links

• "Arformoterol". Drug Information Portal. U.S. National Library of Medicine.
• "Arformoterol tartrate". Drug Information Portal. U.S. National Library of Medicine.